IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10993907 B1

PDFFull Text
Date of Patent:
May. 04, 2021

Filed:

Apr. 06, 2017

Glucono delta-lactone for treatment of vaginal fungal infections

Applicant:

Gedea Biotech Ab, Lund, SE;

Inventors:

Ulf Ellervik, Loddekopinge, SE;

Olov Sterner, Malmo, SE;

Helena Strevens, Lund, SE;

Sophie Manner, Helsingborg, SE;

Assignee:

Gedea Biotech AB, Lund, SE;

Attorneys:

Dinsmore & Shohl LLP

Weston R. Gould

Primary Examiner:

Jianfeng Song

Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 9/02 (2006.01); A61K 9/20 (2006.01); A61K 31/7004 (2006.01); A61K 31/4174 (2006.01); A61K 31/496 (2006.01); A61K 31/4196 (2006.01); A61K 31/351 (2006.01); A61K 31/513 (2006.01); A61K 31/4164 (2006.01); A61P 31/10 (2006.01); F27D 1/16 (2006.01); F27B 14/00 (2006.01); F27B 14/10 (2006.01); H05B 6/24 (2006.01); F27B 14/06 (2006.01); F27B 3/12 (2006.01); A61K 31/366 (2006.01); F27B 14/08 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0036 (2013.01); A61K 9/0034 (2013.01); A61K 9/02 (2013.01); A61K 9/20 (2013.01); A61K 31/351 (2013.01); A61K 31/366 (2013.01); A61K 31/4164 (2013.01); A61K 31/4174 (2013.01); A61K 31/4196 (2013.01); A61K 31/496 (2013.01); A61K 31/513 (2013.01); A61K 31/7004 (2013.01); A61P 31/10 (2018.01); F27B 3/12 (2013.01); F27B 14/00 (2013.01); F27B 14/061 (2013.01); F27B 14/10 (2013.01); F27D 1/1626 (2013.01); H05B 6/24 (2013.01); F27B 2014/066 (2013.01); F27B 2014/0837 (2013.01);
Abstract

The present invention relates to a pharmaceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipient and glucono δ-lactone, wherein the glucono δ-lactone is present in an amount of 5 to 99 wt % of the formulation. The invention also relates to a pharmaceutical formulation according to the invention for use in the prevention or treatment of a urogenital fungal infection. Furthermore, the invention relates to glucono δ-lactone (formula (III)), for use in the in the prevention or treatment of a fungal infection.

Find Patent Forward Citations

Loading…